Key statistics
On Friday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 3.36, 17.28% above the 52 week low of 2.87 set on Sep 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.41 |
---|---|
High | 3.44 |
Low | 3.31 |
Bid | 3.39 |
Offer | 3.45 |
Previous close | 3.45 |
Average volume | 5.61m |
---|---|
Shares outstanding | 62.40m |
Free float | 61.39m |
P/E (TTM) | -- |
Market cap | 209.67m USD |
EPS (TTM) | -0.3507 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Fulcrum Therapeutics to Participate in Upcoming September Conferences
- Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
- Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
- Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
- Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
More ▼